Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we.
Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we. World J Gastroenterol. 2019 Aug 07;25(29):3842-3848 Authors: Tsoulfas G Abstract Although hepatocellular carcinoma (HCC) is as prevalent as ever as a cancer-related mortality, and some would even argue that it is increasing, the pattern of its etiologies has been changing. Specifically, the domination of viral hepatitis C virus is being overcome, partly because of the emergence of the antiviral treatments, and partly because of the significant increase, especially in developed countries, of the combination of obesity, diabetes, metabolic syndrome, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. This editorial will explore the interconnection of this group of diseases and how they are linked to HCC. More importantly, it will argue that this shift in HCC etiology essentially means that we have to change how we approach the treatment of HCC, by changing our focus (and resources) to earlier stages of the disease development in order to prevent the appearance and progression of HCC. PMID: 31413522 [PubMed - in process]
Conclusion RE may mitigate tumor growth and tumor malignancy parameters such as lower histopathological grade, assuming less nuclear pleomorphism and mitotic cells, smaller viable tumor area, and decreased tumor cell proliferation in both adenocarcinomas. In addition, RE induced tumor vascularization.
Conclusion Our study provides novel evidence that EXE-induced antisenescence against metabolic distress in the hippocampus may be a key neuroprotective mechanism, preventing neuroinflammation and oxidative stress.
Purpose Low-attenuation muscle (LAM) area at mid-thigh, a computed tomography (CT)–derived index of intramuscular lipids, is associated with insulin resistance, obesity, and type 2 diabetes. The present study aimed at testing the hypothesis that changes in LAM area in trunk muscles from a single abdominal scan could provide relevant information to evaluate the effects of a lifestyle intervention without the use of a mid-thigh CT scan. Methods Cardiometabolic risk variables, including waist circumference, lipoprotein–lipid profile, glucose tolerance, and cardiorespiratory fitness, were assessed in a sample ...
Authors: Nisker J Abstract Dissolution of Canada's single-tiered health system is now before the Supreme Court of British Columbia and will soon be before the Supreme Court of Canada. If our Supreme Court justices are persuaded to dissolve the Canada Health Act, financially advantaged Canadians will be permitted to purchase privileged access to physicians, diagnostic tests, and surgical facilities. This queue jumping will diminish access for the socioeconomically disadvantaged, among whom women are overrepresented, including women living with disabilities, women of Indigenous heritage, and women who have recently i...
This study investigated whether periodontal treatment might improve glycemic control in patients with chronic periodontitis and type 2 diabetes mellitus, and which modality offers most benefit.BMC Oral Health
CONCLUSIONS: LL-37 concentrations were highest in patients with T2DM+CP when compared with controls. LL-37 was positively correlated with age. HNP 1-3 levels were increased in groups with DM when compared to the groups without periodontitis. The role of AMPs is vital in the immunoinflammatory response in the pathogenesis of periodontitis and DM. PMID: 31522161 [PubMed - in process]
CONCLUSION: Prevalence of severe periodontitis was 10.6%, a lower percentage than other epidemiological studies in Latin America; but still a high proportion of individuals, which would support the importance of preventive and treatment strategies for the country. PMID: 31522152 [PubMed - in process]
CONCLUSIONS: RC individuals in public or academic PMT programs presented with lower periodontal retreatment needs and progression of periodontitis, as well as tooth loss when compared to IC individuals. PMID: 31522149 [PubMed - in process]
Two powerhouses in pharma and medtech are working together to help people with diabetes better manage their condition. Abbott Laboratories and Sanofi will collaborate to integrate glucose sensing and insulin delivery technologies. The two companies will take an innovative approach to connected care by developing tools that combine the Abbott Park, Il-based companyâs FreeStyle Libre technology with Paris-based Sanofiâ²s insulin dosing information. Initially, the collaboration enables data sharing, at the consent of the user, between Abbottâ²s FreeStyle Libre mobile app and...
More News: Alcoholism | Cancer | Cancer & Oncology | Carcinoma | Diabetes | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology